Pemphigus Vulgaris disease mechanism in adults
Pemphigus Vulgaris (PV) is a rare, chronic autoimmune blistering disorder primarily affecting adults. It is characterized by the formation of painful blisters and erosions on the skin and mucous membranes, particularly in the mouth. Understanding the disease mechanism of PV in adults involves exploring how the immune system mistakenly targets the body’s own tissues, leading to the characteristic blistering.
At the core of PV’s pathophysiology is an autoimmune response directed against components of the skin’s structural framework. Specifically, the immune system produces autoantibodies—mainly immunoglobulin G (IgG)—that target desmogleins, which are cadherin-type cell adhesion molecules. In PV, the primary targets are desmoglein 3 and, in some cases, desmoglein 1. These proteins are integral to desmosomes, specialized structures that facilitate adhesion between keratinocytes, the predominant cell type in the epidermis.
The binding of autoantibodies to desmogleins disrupts their function, weakening the bonds that hold keratinocytes together. This loss of cell-cell adhesion, known as acantholysis, causes keratinocytes to detach from each other. The result is the formation of intraepidermal clefts and blistering. Because these autoantibodies are directed against desmogleins located primarily in the lower layers of the epidermis and mucous membranes, blister formation often begins in the oral mucosa before extending to the skin.
The immune response in PV is multifaceted. B cells produce pathogenic autoantibodies against desmogleins, while T-helper cells play a role in modulating this activity. The exact triggers for this autoimmune response are not fully understood, but genetic predispositions, environmental factors such as stress or infections, and certain medications may contribute to disease onset in susceptible adults.
The pathogenic autoantibodies not only interfere with keratinocyte adhesion but can also activate complement pathways and recruit inflammatory cells. This immune activation exacerbates tissue damage, leading to deeper erosions and increasing the risk of secondary infections. The chronic nature of PV involves a cycle of antibody production, tissue damage, and ongoing immune dysregulation.
Treatment strategies aim to suppress this abnormal immune response. Corticosteroids remain the mainstay, reducing antibody production and inflammation. Immunosuppressive agents such as azathioprine, mycophenolate mofetil, or cyclophosphamide are often added to enhance control. Recent advances include biologic therapies like rituximab, an anti-CD20 monoclonal antibody, which targets B cells directly, reducing autoantibody levels and inducing remission.
In summary, Pemphigus Vulgaris in adults results from an autoimmune attack where autoantibodies disrupt keratinocyte adhesion by targeting desmogleins. This leads to intraepidermal blistering and mucocutaneous erosions, with the disease process driven by a complex interplay of immune dysregulation. Understanding these mechanisms is crucial for developing targeted therapies and improving patient outcomes.
